Business
Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies will air interviews with Connect Biopharma Holdings Limited (Nasdaq:CNTB) and Bimergen Energy Corp. (OCTQB:BESS) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...
About this update from Connect Biopharma Holdings Limited
[{"type":"text","content":"ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies will air interviews with Connect Biopharma Holdings Limited (Nasdaq:CNTB) and Bimergen Energy Corp. (OCTQB:BESS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, November 15, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.","length":396,"tagName":"p"},{"type":"text","content":"Access the interviews in their entirety at:","length":43,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"CNTB:https://www.redchip.com/assets/access/cntb_access","length":54,"tagName":"p"}]},{"val":[{"type":"text","content":"BESS: https://www.redchip.com/assets/access/bess_access","length":55,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":109,"olType":false},{"type":"text","content":"In an exclusive interview, Barry Quart, PharmD, CEO of Connect Biopharma, will appear on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss how the company is advancing next-generation biologic therapies designed to transform treatment for severe respiratory diseases. Connect Biopharma's lead candidate, rademikibart, is a differentiated, next-generation monoclonal antibody targeting IL-4Rα with the potential to set a new standard in the treatment of acute and chronic asthma and COPD. Backed by strong global Phase 2 data showing rapid improvement in lung function and a favorable safety profile, rademikibart is now being advanced through Phase 2 "Seabreeze STAT" studies in acute exacerbations of asthma and COPD, with topline data expected in the first half of 2026. Dr. Quart also provides insight into the company's regulatory path to Phase 3 trials, robust financial position with cash runway into 2027, and large commercial opportunity exceeding $5 billion in combined peak sales potential across asthma and COPD.","length":1059,"tagName":"p"},{"type":"text","content":"Robert J. Brilon, co-CEO of Bimergen, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss Bimergen's expanding portfolio of utility-scale battery energy storage system (BESS) projects designed to meet surging U.S. electricity demand. The Company currently controls 23 development-stage projects totaling approximately 2.0 GW of planned capacity ...